

Virtanen SS, Tuomela J, Sandholm J, Ishizu T, Väänänen HK, Härkönen PL. Alendronate-induced disruption of actin cytoskeleton is associated, with cofilin down regulation in PC-3 prostate cancer cells. **Oncotarget 9(66):32593-32608, 2018**

Kähkönen TE, Ivaska KK, Jian M, Büki KG, Väänänen HK, Härkönen PL. Role of fibroblast growth factor receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes. **Mol Cell Endo 461:194-204, 2017**

Yu L, Toriseva M, Tuomala M, Elo T, Tuomela J, Seikkula H, Nurmi M, Boström PJ, Mirtti T, Taimen P, Alanen K, Kallajoki M, Nees M, Härkönen P. Increased expression of fibroblast growth factor 13 (FGF13) in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. **Int J Cancer 139(1):140-52, 2016**

Eigéliené N, Kangas L, Hellmer C, Kauko T, Erkkola R, Härkönen P. Effects of ospemifene, a novel selective estrogen receptor modulator in human breast tissue ex vivo. **Menopause 23(7):719-30, 2016**

Semenas J, Hedblom A, Sarwar M, Miftakhova R, Larsson R, Shcherbina L, Johansson M., Söderlind A., Härkönen P., Sterner O., Liao Persson J.: Novel role of PI3K/Akt-related PIP5K1 α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. **Proc Natl Acad Sci U S A 2;111(35):E3689-98, 2014**

Elo T, Yu L, Valve E, Mäkelä S, Härkönen P. Deficiency of ER beta and prostate tumorigenesis in FGF8b transgenic mice. **Endocr Rel Cancer 21(4):677, 2014**

Määttä J, Büki K, Gu G, Alanne M, Vääräniemi J, Liljenbäck H, Poutanen M, Härkönen P, Väänänen K. Inactivation of estrogen receptor alpha in bone forming cells induces bone loss in female mice. **FASEB J. 27(2):478-88, 2013**

Eigèlienè N, Hurme S, Erkkola R, Härkönen P. Androgens inhibit the stimulatory action of 17 β -estradiol in human breast in tissue culture. **J Clin Endocrinol Metab 97(7):E1116-27, 2012**

Nilsson EM, Brokken LJM, Narvi, E., Kallio, M., Härkönen PL. Identification of novel FGF-8b target genes associated with regulation of cell cycle and proliferation in breast cancer cells. **Mol Cell Endocrinol 6; 358(1):104-15, 2012**

Berglund P, Lehn S, Nilsson K, Tobin NB, Jirström K, Härkönen P, Landberg G: Downregulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. **Am J Pathol 177(6) 2886-2897, 2010**

Elo T, Valve EM, Seppänen JA, Vuorikoski H, Mäkelä SM, Poutanen M, Kujala PM, Härkönen PL: Fibroblast growth factor 8b (FGF-8b) –induced stromal activation is associated with development of mixed mPIN, adenocarcinoma and sarcoma lesions in the prostate of transgenic mice. **Neoplasia 12 (11) 915-27, 2010**

Tassidis H, Brokken LJS, Ehrnström R, Jirström K, Pontén F, Ulmert D, Bjartell A, Härkönen P, Gjörlöff Wingren A: Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. **Int J Cancer 126, 2296-307, 2010**

Säfholm A, Tuomela J, Rosenkvist J, Dejmek J, Härkönen P, Andersson TA. Wnt-5a-derived hexapeptide radically impairs 4T1 breast cancer metastasis in mice. **Clin Cancer Res** 14(20):6556-63, 2008

Wegiel B, Bjartell A, Tuomela J, Helczynski L, Nilsson E, Härkönen P, Liao Persson J. A novel role for cyclin A1 in promoting prostate cancer invasion, acting as a coregulator of AR and a potential transcriptional activator on genes encoding MMP-2 and VEGF. **J Natl Cancer Inst** 100 (14):1022-36, 2008

Valta MP, Tuomela JM, Bjartell A, Valve EM, Väänänen HK, Härkönen PL. FGF-8 is involved in prostate cancer bone metastasis. **Int J Cancer** 123(1):22-31, 2008

Mattila MM, Härkönen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. **Cytokin Growth Factor Rev** 18(3-4):257-266, 2007